AG6033
AG6033 is a CRBN-dependent molecular glue degrader targeting GSPT1 (DC50 of 2.5 μM) and IKZF1. AG6033 induces degradation of GSPT1 via π-π stacking and hydrogen bonding with CRBN in a partially CRBN-dependent manner, decreases IKZF1 levels, and promotes degradation of CRBN substrates. AG6033 induces apoptosis in lung adenocarcinoma cells. AG6033 can be used for the research of lung cancer.
For research use only. We do not sell to patients.
- CAS No.: 329706-62-9
- Formula: C30H23N5O4
- Molecular Weight:517.53
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Eukaryotic Release Factor (eRF) Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
eRF3a/GSPT1 2.5 μM (DC50) |
IKZF1 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.853 μM
Compound: AG6033
|
Antitumor activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay
Antitumor activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay
|
[PMID: 35413617] |
In Vitro
AG6033 induces CRBN-dependent degradation of GSPT1 and IKZF1, inhibits A549 cell proliferation with an IC50 of 0.853 μM, and triggers apoptosis in A549 cells[1].
AG6033 (1-10 μM; 24 h) promotes apoptosis of human lung adenocarcinoma A549 cells in a concentration-dependent manner[2].
AG6033 (1.25-5 μM) induces degradation of the CRBN neosubstrates IKZF1 and GSPT1 in human lung adenocarcinoma A549, human multiple myeloma U266, and human acute myeloid leukemia OCI-AML2 cells, with no significant effect on CK1α levels[2].
AG6033 (1-31.6 μM; 48 h) exerts a cytotoxic effect on human multiple myeloma U266 cells that is CRBN-dependent, as CRBN knockout confers resistance to AG6033-induced viability loss[2].
AG6033 achieves structural matching with CRBN and binds via key π-π stacking interactions with TRP380, TRP386, TRP400, and HIS397, plus a hydrogen bond with GLU377[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human lung adenocarcinoma A549 cells
-
Concentration:0.064 μM, 0.32 μM, 1.6 μM, 8 μM, 40 μM
-
Incubation Time:48 h
-
Result:Potently inhibited the viability of A549 cells, with an IC50 value of 0.853 μM.
-
Cell Line:human lung adenocarcinoma A549 cells
-
Concentration:1 μM, 5 μM, 10 μM
-
Incubation Time:24 h
-
Result:Increased the proportion of apoptotic A549 cells in a concentration-dependent manner.
At 1 μM, early and late apoptotic cells accounted for 5.66% and 5.39% of the population, respectively.
At 5 μM, early and late apoptotic cells accounted for 25.8% and 22.0% of the population, respectively.
At 10 μM, early and late apoptotic cells accounted for 36.2% and 29.1% of the population, respectively.
Induced apoptosis levels comparable to that induced by 1 μM doxorubicin at 5 μM.
-
Cell Line:CRBN-knockout and control human multiple myeloma U266 cells
-
Concentration:1 μM, 3.16 μM, 10 μM, 31.6 μM
-
Incubation Time:48 h
-
Result:Rendered CRBN-knockout U266 cells resistant, as shown by significantly higher cell viability in sg-CRBN cells compared to sg-NC cells at equivalent concentrations.
Chemical Information
-
CAS No. 329706-62-9
-
Molecular Weight 517.53
-
Formula C30H23N5O4
-
SMILES
O=C(N/N=C1C(N(CC(NC2=CC=CC=C2)=O)C3=C\1C=CC=C3)=O)C4=CC=CC(NC(C5=CC=CC=C5)=O)=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)